U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C24H25ClFN5O3
Molecular Weight 485.9393
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CANERTINIB

SMILES

C=CC(=Nc1cc2c(cc1OCCCN3CCOCC3)ncnc2Nc4ccc(c(c4)Cl)F)O

InChI

InChIKey=OMZCMEYTWSXEPZ-UHFFFAOYSA-N
InChI=1S/C24H25ClFN5O3/c1-2-23(32)30-21-13-17-20(14-22(21)34-9-3-6-31-7-10-33-11-8-31)27-15-28-24(17)29-16-4-5-19(26)18(25)12-16/h2,4-5,12-15H,1,3,6-11H2,(H,30,32)(H,27,28,29)

HIDE SMILES / InChI

Molecular Formula C24H25ClFN5O3
Molecular Weight 485.9393
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Canertinib or CI-1033 (N-[4-[N-(3-Chloro-4-fluorophenyl)amino]-7-[3-(4-morpholinyl)propoxy]quinazolin-6-yl]acrylamide) is a pan-erbB tyrosine kinase inhibitor. It selectively inhibits erbB1 (epidermal growth factor receptor), erbB2, erbB3, and erbB4 without inhibiting tyrosine kinase activity of receptors such as platelet-derived growth factor receptor, fibroblast growth factor receptor, and insulin receptor, even at high concentrations. Canertinib was under development by Pfizer Inc as a potential treatment for cancer.

Approval Year

Doses

Doses

DosePopulationAdverse events​
337.5 mg 3 times / week multiple, intravenous (total daily dose)
Highest studied dose
Dose: 337.5 mg, 3 times / week
Route: intravenous
Route: multiple
Dose: 337.5 mg, 3 times / week
Sources:
unhealthy
n = 7
Health Status: unhealthy
Condition: advanced nonhematologic malignancies
Sex: M+F
Food Status: UNKNOWN
Population Size: 7
Sources:
DLT: hypersensitivity reaction, diarrhea...
Dose limiting toxicities:
hypersensitivity reaction (grade 3, 2 patients)
diarrhea (grade 3, 2 patients)
Sources:
500 mg 3 times / week multiple, intravenous (total daily dose)
Highest studied dose
Dose: 500 mg, 3 times / week
Route: intravenous
Route: multiple
Dose: 500 mg, 3 times / week
Sources:
unhealthy
n = 3
Health Status: unhealthy
Condition: advanced nonhematologic malignancies
Sex: M+F
Food Status: UNKNOWN
Population Size: 3
Sources:
DLT: Myalgia, syncope...
Dose limiting toxicities:
Myalgia (grade 3, 2 patients)
syncope (2 patients)
Sources:
750 mg 1 times / day multiple, oral (total daily dose)
Highest studied dose
Dose: 750 mg, 1 times / day
Route: oral
Route: multiple
Dose: 750 mg, 1 times / day
Sources:
unhealthy
n = 3
Health Status: unhealthy
Condition: refractory cancer
Sex: M+F
Food Status: UNKNOWN
Population Size: 3
Sources:
DLT: emesis, rash...
Other AEs: Diarrhea...
Dose limiting toxicities:
emesis (grade 2, 1 pt)
rash (grade 2, 1 pt)
mouth ulcer (grade 2, 1 pt)
emesis (grade 3, 1 pt)
Other AEs:
Diarrhea (grade 1-2, 2 patients)
Sources:
225 mg 3 times / week multiple, intravenous (total daily dose)
MTD
Dose: 225 mg, 3 times / week
Route: intravenous
Route: multiple
Dose: 225 mg, 3 times / week
Sources:
unhealthy
n = 7
Health Status: unhealthy
Condition: advanced nonhematologic malignancies
Sex: M+F
Food Status: UNKNOWN
Population Size: 7
Sources:
Other AEs: Dyspnea, Infection...
Other AEs:
Dyspnea (1 pt)
Infection (3 patients)
Thrombocytopenia (1 pt)
Cutaneous toxicities (7 patients)
Pain (2 patients)
Asthenia (2 patients)
Vasodilation (2 patients)
Stomatitis (2 patients)
Myalgia (2 patients)
Vomiting (2 patients)
Nausea (2 patients)
Sources:
650 mg 1 times / day multiple, oral (total daily dose)
MTD
Dose: 650 mg, 1 times / day
Route: oral
Route: multiple
Dose: 650 mg, 1 times / day
Sources:
unhealthy
n = 8
Health Status: unhealthy
Condition: Refractory cancer
Sex: M+F
Food Status: UNKNOWN
Population Size: 8
Sources:
DLT: thrombocytopenia...
Other AEs: Emesis, rash...
Dose limiting toxicities:
thrombocytopenia (grade 4, 1 pt)
Other AEs:
Emesis (grade 3, 1 pt)
rash (grade 1-2, 7 patients)
Hypersensitivity (grade 1-2, 3 patients)
Mucositis (grade 1-2, 6 patients)
Nausea (grade 1-2, 5 patients)
iarrhea (grade 1-2, 3 patients)
Sources:
200 mg 1 times / day multiple, oral (total daily dose)
Studied dose
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy
n = 52
Health Status: unhealthy
Condition: ovarian cancer
Sex: F
Food Status: UNKNOWN
Population Size: 52
Sources:
Disc. AE: Diarrhea...
Other AEs: Abdominal pain, Asthenia...
AEs leading to
discontinuation/dose reduction:
Diarrhea (13%)
Other AEs:
Abdominal pain (13%)
Asthenia (13%)
Sources:
50 mg 1 times / day multiple, oral (total daily dose)
Studied dose
Dose: 50 mg, 1 times / day
Route: oral
Route: multiple
Dose: 50 mg, 1 times / day
Sources:
unhealthy
n = 53
Health Status: unhealthy
Condition: ovarian cancer
Sex: F
Food Status: UNKNOWN
Population Size: 53
Sources:
Disc. AE: diarrhea, Abdominal pain...
AEs leading to
discontinuation/dose reduction:
diarrhea (10%)
Abdominal pain (10%)
Asthenia (10%)
Sources:
50 mg 1 times / day multiple, oral (total daily dose)
Studied dose
Dose: 50 mg, 1 times / day
Route: oral
Route: multiple
Dose: 50 mg, 1 times / day
Sources:
unhealthy
n = 7
Health Status: unhealthy
Condition: Refractory cancer
Sex: M+F
Food Status: UNKNOWN
Population Size: 7
Sources:
DLT: Thrombocytopenia...
Dose limiting toxicities:
Thrombocytopenia (grade 3, 1 pt)
Sources:
560 mg 1 times / day multiple, oral (total daily dose)
Studied dose
Dose: 560 mg, 1 times / day
Route: oral
Route: multiple
Dose: 560 mg, 1 times / day
Sources:
unhealthy
n = 8
Health Status: unhealthy
Condition: refractory cancer
Sex: M+F
Food Status: UNKNOWN
Population Size: 8
Sources:
DLT: Hypersensitivity...
Dose limiting toxicities:
Hypersensitivity (grade 3, 1 pt)
Sources:
AEs

AEs

AESignificanceDosePopulation
diarrhea grade 3, 2 patients
DLT
337.5 mg 3 times / week multiple, intravenous (total daily dose)
Highest studied dose
Dose: 337.5 mg, 3 times / week
Route: intravenous
Route: multiple
Dose: 337.5 mg, 3 times / week
Sources:
unhealthy
n = 7
Health Status: unhealthy
Condition: advanced nonhematologic malignancies
Sex: M+F
Food Status: UNKNOWN
Population Size: 7
Sources:
hypersensitivity reaction grade 3, 2 patients
DLT
337.5 mg 3 times / week multiple, intravenous (total daily dose)
Highest studied dose
Dose: 337.5 mg, 3 times / week
Route: intravenous
Route: multiple
Dose: 337.5 mg, 3 times / week
Sources:
unhealthy
n = 7
Health Status: unhealthy
Condition: advanced nonhematologic malignancies
Sex: M+F
Food Status: UNKNOWN
Population Size: 7
Sources:
syncope 2 patients
DLT
500 mg 3 times / week multiple, intravenous (total daily dose)
Highest studied dose
Dose: 500 mg, 3 times / week
Route: intravenous
Route: multiple
Dose: 500 mg, 3 times / week
Sources:
unhealthy
n = 3
Health Status: unhealthy
Condition: advanced nonhematologic malignancies
Sex: M+F
Food Status: UNKNOWN
Population Size: 3
Sources:
Myalgia grade 3, 2 patients
DLT
500 mg 3 times / week multiple, intravenous (total daily dose)
Highest studied dose
Dose: 500 mg, 3 times / week
Route: intravenous
Route: multiple
Dose: 500 mg, 3 times / week
Sources:
unhealthy
n = 3
Health Status: unhealthy
Condition: advanced nonhematologic malignancies
Sex: M+F
Food Status: UNKNOWN
Population Size: 3
Sources:
Diarrhea grade 1-2, 2 patients
750 mg 1 times / day multiple, oral (total daily dose)
Highest studied dose
Dose: 750 mg, 1 times / day
Route: oral
Route: multiple
Dose: 750 mg, 1 times / day
Sources:
unhealthy
n = 3
Health Status: unhealthy
Condition: refractory cancer
Sex: M+F
Food Status: UNKNOWN
Population Size: 3
Sources:
emesis grade 2, 1 pt
DLT
750 mg 1 times / day multiple, oral (total daily dose)
Highest studied dose
Dose: 750 mg, 1 times / day
Route: oral
Route: multiple
Dose: 750 mg, 1 times / day
Sources:
unhealthy
n = 3
Health Status: unhealthy
Condition: refractory cancer
Sex: M+F
Food Status: UNKNOWN
Population Size: 3
Sources:
mouth ulcer grade 2, 1 pt
DLT
750 mg 1 times / day multiple, oral (total daily dose)
Highest studied dose
Dose: 750 mg, 1 times / day
Route: oral
Route: multiple
Dose: 750 mg, 1 times / day
Sources:
unhealthy
n = 3
Health Status: unhealthy
Condition: refractory cancer
Sex: M+F
Food Status: UNKNOWN
Population Size: 3
Sources:
rash grade 2, 1 pt
DLT
750 mg 1 times / day multiple, oral (total daily dose)
Highest studied dose
Dose: 750 mg, 1 times / day
Route: oral
Route: multiple
Dose: 750 mg, 1 times / day
Sources:
unhealthy
n = 3
Health Status: unhealthy
Condition: refractory cancer
Sex: M+F
Food Status: UNKNOWN
Population Size: 3
Sources:
emesis grade 3, 1 pt
DLT
750 mg 1 times / day multiple, oral (total daily dose)
Highest studied dose
Dose: 750 mg, 1 times / day
Route: oral
Route: multiple
Dose: 750 mg, 1 times / day
Sources:
unhealthy
n = 3
Health Status: unhealthy
Condition: refractory cancer
Sex: M+F
Food Status: UNKNOWN
Population Size: 3
Sources:
Dyspnea 1 pt
225 mg 3 times / week multiple, intravenous (total daily dose)
MTD
Dose: 225 mg, 3 times / week
Route: intravenous
Route: multiple
Dose: 225 mg, 3 times / week
Sources:
unhealthy
n = 7
Health Status: unhealthy
Condition: advanced nonhematologic malignancies
Sex: M+F
Food Status: UNKNOWN
Population Size: 7
Sources:
Thrombocytopenia 1 pt
225 mg 3 times / week multiple, intravenous (total daily dose)
MTD
Dose: 225 mg, 3 times / week
Route: intravenous
Route: multiple
Dose: 225 mg, 3 times / week
Sources:
unhealthy
n = 7
Health Status: unhealthy
Condition: advanced nonhematologic malignancies
Sex: M+F
Food Status: UNKNOWN
Population Size: 7
Sources:
Asthenia 2 patients
225 mg 3 times / week multiple, intravenous (total daily dose)
MTD
Dose: 225 mg, 3 times / week
Route: intravenous
Route: multiple
Dose: 225 mg, 3 times / week
Sources:
unhealthy
n = 7
Health Status: unhealthy
Condition: advanced nonhematologic malignancies
Sex: M+F
Food Status: UNKNOWN
Population Size: 7
Sources:
Myalgia 2 patients
225 mg 3 times / week multiple, intravenous (total daily dose)
MTD
Dose: 225 mg, 3 times / week
Route: intravenous
Route: multiple
Dose: 225 mg, 3 times / week
Sources:
unhealthy
n = 7
Health Status: unhealthy
Condition: advanced nonhematologic malignancies
Sex: M+F
Food Status: UNKNOWN
Population Size: 7
Sources:
Nausea 2 patients
225 mg 3 times / week multiple, intravenous (total daily dose)
MTD
Dose: 225 mg, 3 times / week
Route: intravenous
Route: multiple
Dose: 225 mg, 3 times / week
Sources:
unhealthy
n = 7
Health Status: unhealthy
Condition: advanced nonhematologic malignancies
Sex: M+F
Food Status: UNKNOWN
Population Size: 7
Sources:
Pain 2 patients
225 mg 3 times / week multiple, intravenous (total daily dose)
MTD
Dose: 225 mg, 3 times / week
Route: intravenous
Route: multiple
Dose: 225 mg, 3 times / week
Sources:
unhealthy
n = 7
Health Status: unhealthy
Condition: advanced nonhematologic malignancies
Sex: M+F
Food Status: UNKNOWN
Population Size: 7
Sources:
Stomatitis 2 patients
225 mg 3 times / week multiple, intravenous (total daily dose)
MTD
Dose: 225 mg, 3 times / week
Route: intravenous
Route: multiple
Dose: 225 mg, 3 times / week
Sources:
unhealthy
n = 7
Health Status: unhealthy
Condition: advanced nonhematologic malignancies
Sex: M+F
Food Status: UNKNOWN
Population Size: 7
Sources:
Vasodilation 2 patients
225 mg 3 times / week multiple, intravenous (total daily dose)
MTD
Dose: 225 mg, 3 times / week
Route: intravenous
Route: multiple
Dose: 225 mg, 3 times / week
Sources:
unhealthy
n = 7
Health Status: unhealthy
Condition: advanced nonhematologic malignancies
Sex: M+F
Food Status: UNKNOWN
Population Size: 7
Sources:
Vomiting 2 patients
225 mg 3 times / week multiple, intravenous (total daily dose)
MTD
Dose: 225 mg, 3 times / week
Route: intravenous
Route: multiple
Dose: 225 mg, 3 times / week
Sources:
unhealthy
n = 7
Health Status: unhealthy
Condition: advanced nonhematologic malignancies
Sex: M+F
Food Status: UNKNOWN
Population Size: 7
Sources:
Infection 3 patients
225 mg 3 times / week multiple, intravenous (total daily dose)
MTD
Dose: 225 mg, 3 times / week
Route: intravenous
Route: multiple
Dose: 225 mg, 3 times / week
Sources:
unhealthy
n = 7
Health Status: unhealthy
Condition: advanced nonhematologic malignancies
Sex: M+F
Food Status: UNKNOWN
Population Size: 7
Sources:
Cutaneous toxicities 7 patients
225 mg 3 times / week multiple, intravenous (total daily dose)
MTD
Dose: 225 mg, 3 times / week
Route: intravenous
Route: multiple
Dose: 225 mg, 3 times / week
Sources:
unhealthy
n = 7
Health Status: unhealthy
Condition: advanced nonhematologic malignancies
Sex: M+F
Food Status: UNKNOWN
Population Size: 7
Sources:
Hypersensitivity grade 1-2, 3 patients
650 mg 1 times / day multiple, oral (total daily dose)
MTD
Dose: 650 mg, 1 times / day
Route: oral
Route: multiple
Dose: 650 mg, 1 times / day
Sources:
unhealthy
n = 8
Health Status: unhealthy
Condition: Refractory cancer
Sex: M+F
Food Status: UNKNOWN
Population Size: 8
Sources:
iarrhea grade 1-2, 3 patients
650 mg 1 times / day multiple, oral (total daily dose)
MTD
Dose: 650 mg, 1 times / day
Route: oral
Route: multiple
Dose: 650 mg, 1 times / day
Sources:
unhealthy
n = 8
Health Status: unhealthy
Condition: Refractory cancer
Sex: M+F
Food Status: UNKNOWN
Population Size: 8
Sources:
Nausea grade 1-2, 5 patients
650 mg 1 times / day multiple, oral (total daily dose)
MTD
Dose: 650 mg, 1 times / day
Route: oral
Route: multiple
Dose: 650 mg, 1 times / day
Sources:
unhealthy
n = 8
Health Status: unhealthy
Condition: Refractory cancer
Sex: M+F
Food Status: UNKNOWN
Population Size: 8
Sources:
Mucositis grade 1-2, 6 patients
650 mg 1 times / day multiple, oral (total daily dose)
MTD
Dose: 650 mg, 1 times / day
Route: oral
Route: multiple
Dose: 650 mg, 1 times / day
Sources:
unhealthy
n = 8
Health Status: unhealthy
Condition: Refractory cancer
Sex: M+F
Food Status: UNKNOWN
Population Size: 8
Sources:
rash grade 1-2, 7 patients
650 mg 1 times / day multiple, oral (total daily dose)
MTD
Dose: 650 mg, 1 times / day
Route: oral
Route: multiple
Dose: 650 mg, 1 times / day
Sources:
unhealthy
n = 8
Health Status: unhealthy
Condition: Refractory cancer
Sex: M+F
Food Status: UNKNOWN
Population Size: 8
Sources:
Emesis grade 3, 1 pt
650 mg 1 times / day multiple, oral (total daily dose)
MTD
Dose: 650 mg, 1 times / day
Route: oral
Route: multiple
Dose: 650 mg, 1 times / day
Sources:
unhealthy
n = 8
Health Status: unhealthy
Condition: Refractory cancer
Sex: M+F
Food Status: UNKNOWN
Population Size: 8
Sources:
thrombocytopenia grade 4, 1 pt
DLT
650 mg 1 times / day multiple, oral (total daily dose)
MTD
Dose: 650 mg, 1 times / day
Route: oral
Route: multiple
Dose: 650 mg, 1 times / day
Sources:
unhealthy
n = 8
Health Status: unhealthy
Condition: Refractory cancer
Sex: M+F
Food Status: UNKNOWN
Population Size: 8
Sources:
Abdominal pain 13%
200 mg 1 times / day multiple, oral (total daily dose)
Studied dose
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy
n = 52
Health Status: unhealthy
Condition: ovarian cancer
Sex: F
Food Status: UNKNOWN
Population Size: 52
Sources:
Asthenia 13%
200 mg 1 times / day multiple, oral (total daily dose)
Studied dose
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy
n = 52
Health Status: unhealthy
Condition: ovarian cancer
Sex: F
Food Status: UNKNOWN
Population Size: 52
Sources:
Diarrhea 13%
Disc. AE
200 mg 1 times / day multiple, oral (total daily dose)
Studied dose
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy
n = 52
Health Status: unhealthy
Condition: ovarian cancer
Sex: F
Food Status: UNKNOWN
Population Size: 52
Sources:
Abdominal pain 10%
Disc. AE
50 mg 1 times / day multiple, oral (total daily dose)
Studied dose
Dose: 50 mg, 1 times / day
Route: oral
Route: multiple
Dose: 50 mg, 1 times / day
Sources:
unhealthy
n = 53
Health Status: unhealthy
Condition: ovarian cancer
Sex: F
Food Status: UNKNOWN
Population Size: 53
Sources:
Asthenia 10%
Disc. AE
50 mg 1 times / day multiple, oral (total daily dose)
Studied dose
Dose: 50 mg, 1 times / day
Route: oral
Route: multiple
Dose: 50 mg, 1 times / day
Sources:
unhealthy
n = 53
Health Status: unhealthy
Condition: ovarian cancer
Sex: F
Food Status: UNKNOWN
Population Size: 53
Sources:
diarrhea 10%
Disc. AE
50 mg 1 times / day multiple, oral (total daily dose)
Studied dose
Dose: 50 mg, 1 times / day
Route: oral
Route: multiple
Dose: 50 mg, 1 times / day
Sources:
unhealthy
n = 53
Health Status: unhealthy
Condition: ovarian cancer
Sex: F
Food Status: UNKNOWN
Population Size: 53
Sources:
Thrombocytopenia grade 3, 1 pt
DLT
50 mg 1 times / day multiple, oral (total daily dose)
Studied dose
Dose: 50 mg, 1 times / day
Route: oral
Route: multiple
Dose: 50 mg, 1 times / day
Sources:
unhealthy
n = 7
Health Status: unhealthy
Condition: Refractory cancer
Sex: M+F
Food Status: UNKNOWN
Population Size: 7
Sources:
Hypersensitivity grade 3, 1 pt
DLT
560 mg 1 times / day multiple, oral (total daily dose)
Studied dose
Dose: 560 mg, 1 times / day
Route: oral
Route: multiple
Dose: 560 mg, 1 times / day
Sources:
unhealthy
n = 8
Health Status: unhealthy
Condition: refractory cancer
Sex: M+F
Food Status: UNKNOWN
Population Size: 8
Sources:
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(phenylamino)quinazoline- and 4-(phenylamino)pyrido[3,2-d]pyrimidine-6-acrylamides bearing additional solubilizing functions.
2000 Apr 6
Increased bioavailability of intravenous versus oral CI-1033, a pan erbB tyrosine kinase inhibitor: results of a phase I pharmacokinetic study.
2006 Aug 1
Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
2007 Mar
Activation state-dependent binding of small molecule kinase inhibitors: structural insights from biochemistry.
2010 Nov 24
Comprehensive analysis of kinase inhibitor selectivity.
2011 Oct 30
Patents

Patents

Sample Use Guides

According to the phase I pharmacokinetic study canertinib (CI-1033) was safely given i.v. up to 225 mg/dose on a thrice-weekly schedule, with evidence of antitumor activity. At equivalent doses, the bioavailability of i.v. CI-1033 is thrice that of the oral formulation.
Route of Administration: Other
The effect of canertinib (CI-1033) on esophageal cancer cell proliferation was investigated in the TT, TE2, TE6 and TE10 cell lines. After one day of treatment with CI-1033 (0.1-5.0 nM) significant inhibition of cell growth was observed in all cell lines at all concentrations of CI-1033 examined. The dose of CI-1033 required to inhibit the cell growth was as low as 0.1 nM. The inhibitory effect of CI-1033 on cancer cell growth was dose- and time-dependent.
Substance Class Chemical
Created
by admin
on Sat Jun 26 06:32:47 UTC 2021
Edited
by admin
on Sat Jun 26 06:32:47 UTC 2021
Record UNII
C78W1K5ASF
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CANERTINIB
INN   MI   WHO-DD  
INN  
Official Name English
CANERTINIB [MI]
Common Name English
CANERTINIB [WHO-DD]
Common Name English
N-(4-(3-CHLORO-4-FLUOROPHENYL)AMINO)-7-(3-MORPHOLIN-4-YL)PROPOXY)QUINAZOLIN-6-YL)PROP-2-ENAMIDE
Common Name English
2-PROPENAMIDE, N-(4-((3-CHLORO-4-FLUOROPHENYL)AMINO)-7-(3-(4-MORPHOLINYL)PROPOXY)-6-QUINAZOLINYL)-
Systematic Name English
CANERTINIB [INN]
Common Name English
PD-183805
Code English
Classification Tree Code System Code
NCI_THESAURUS C2167
Created by admin on Sat Jun 26 06:32:47 UTC 2021 , Edited by admin on Sat Jun 26 06:32:47 UTC 2021
Code System Code Type Description
ChEMBL
CHEMBL31965
Created by admin on Sat Jun 26 06:32:47 UTC 2021 , Edited by admin on Sat Jun 26 06:32:47 UTC 2021
PRIMARY
CAS
267243-28-7
Created by admin on Sat Jun 26 06:32:47 UTC 2021 , Edited by admin on Sat Jun 26 06:32:47 UTC 2021
PRIMARY
WIKIPEDIA
CANERTINIB
Created by admin on Sat Jun 26 06:32:47 UTC 2021 , Edited by admin on Sat Jun 26 06:32:47 UTC 2021
PRIMARY
INN
8256
Created by admin on Sat Jun 26 06:32:47 UTC 2021 , Edited by admin on Sat Jun 26 06:32:47 UTC 2021
PRIMARY
DRUG BANK
DB05424
Created by admin on Sat Jun 26 06:32:47 UTC 2021 , Edited by admin on Sat Jun 26 06:32:47 UTC 2021
PRIMARY
EVMPD
SUB25399
Created by admin on Sat Jun 26 06:32:47 UTC 2021 , Edited by admin on Sat Jun 26 06:32:47 UTC 2021
PRIMARY
MERCK INDEX
M3017
Created by admin on Sat Jun 26 06:32:47 UTC 2021 , Edited by admin on Sat Jun 26 06:32:47 UTC 2021
PRIMARY Merck Index
EPA CompTox
267243-28-7
Created by admin on Sat Jun 26 06:32:47 UTC 2021 , Edited by admin on Sat Jun 26 06:32:47 UTC 2021
PRIMARY
FDA UNII
C78W1K5ASF
Created by admin on Sat Jun 26 06:32:47 UTC 2021 , Edited by admin on Sat Jun 26 06:32:47 UTC 2021
PRIMARY
PUBCHEM
156414
Created by admin on Sat Jun 26 06:32:47 UTC 2021 , Edited by admin on Sat Jun 26 06:32:47 UTC 2021
PRIMARY
NCI_THESAURUS
C77588
Created by admin on Sat Jun 26 06:32:47 UTC 2021 , Edited by admin on Sat Jun 26 06:32:47 UTC 2021
PRIMARY
Related Record Type Details
TRANSPORTER -> INHIBITOR
SALT/SOLVATE -> PARENT
Related Record Type Details
ACTIVE MOIETY